Table 2.
Multivariable proportional hazards model of progression-free survival at 2 months predicting overall survival stratified on study
| Variables | Training data set (II)
|
Testing data set (III)
|
|---|---|---|
| Adjusted HR (95% CI; P-value)* | Adjusted HR (95% CI; P-value)* | |
| Any progression at 2 months | ||
| Yes versus no | 3.39 (1.79–6.41; <0.0001) | 2.48 (1.81–3.40; <0.0001) |
| Age | 0.98 (0.94–1.03; 0.469) | 1.01 (0.99–1.02; 0.414) |
| Sex | ||
| Female versus male | 1.54 (0.64–3.72; 0.337) | 0.84 (0.59–1.19; 0.326) |
| ECOG PS | ||
| 1 versus 0 | 3.81 (0.50–28.93; 0.196) | 2.02 (1.40–2.93; <0.0001) |
| Previous lines of chemotherapy | ||
| ≥3 versus 2 | 1.47 (0.78–2.78; 0.235) | 0.79 (0.56–1.07; 0.126) |
| Metastatic sites (n) | ||
| >2 versus ≤2 | 1.54 (0.73–3.23; 0.258) | 1.46 (1.05–2.03; 0.023) |
Note:
*
Adjusted for age, sex, ECOG PS, previous lines of chemotherapy and number of metastatic sites in Cox model.
Abbreviations: HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; PS, performance status.